A response to the commentary "Indolamine 2,3-dioxygenase regulation and neuropsychiatric symptoms" by Loftis, J.M. on "Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms" by Udina, M., Moreno-España, J., Navinés, R., Gimenez, D., Langohr, K., Gratacòs, M., Capuron, L., de la Torre, R., Solà, R., Martin-Santos, R. http:\\dx.doi.org/10.1016/j.psyneuen.2013.03.007

Psychoneuroendocrinology. 2013 Sep;38(9):1830-1. doi: 10.1016/j.psyneuen.2013.05.019. Epub 2013 Jun 28.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antiviral Agents / adverse effects*
  • Anxiety / chemically induced*
  • Depression / chemically induced*
  • Fatigue / chemically induced*
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • INDEL Mutation*
  • Interferon-alpha / adverse effects*
  • Interleukin-6 / genetics*
  • Point Mutation*
  • Polyethylene Glycols / adverse effects*
  • Recombinant Proteins / adverse effects
  • Serotonin / physiology*
  • Serotonin Plasma Membrane Transport Proteins / genetics*

Substances

  • Antiviral Agents
  • IL6 protein, human
  • Interferon-alpha
  • Interleukin-6
  • Recombinant Proteins
  • SLC6A4 protein, human
  • Serotonin Plasma Membrane Transport Proteins
  • Serotonin
  • Polyethylene Glycols
  • peginterferon alfa-2a